Genix Pharmaceuticals Corporation Enters into Exclusive License and Supply Agreement for Canada’s First Generic Thyroid MedicationApril 1, 2021Vancouver, British Columbia, April 1, 2021 – Genix Pharmaceuticals Corporation…
Genix Pharmaceuticals Corporation prepares to file Abbreviated New Drug Submissions (ANDS) for its first ten Ophthalmic Drugs with Health CanadaMarch 22, 2021Genix Introduces Paul Chow to the Board of Directors Vancouver,…
Genix Pharmaceuticals Corporation Announces Appointment of New Chief Financial OfficerDecember 15, 2020Vancouver, British Columbia, December 15th, 2020 — Genix Pharmaceuticals Corporation…
Genix Pharmaceuticals Corporation Announces AGM Results and Welcomes New DirectorSeptember 22, 2020Vancouver, British Columbia, September 22, 2020 — Genix Pharmaceuticals Corporation (TSX-V: GENX) (“GENIX” or…
Genix Pharmaceuticals Corporation Announces Closing of Second Tranche Financing and closing of acquisition of rights to Nutraceutical Products Sucanon® and Renochlor®August 6, 2020VANCOUVER, BRITISH COLUMBIA, August 6, 2020 — Genix Pharmaceuticals Corporation…
Genix Pharmaceuticals Corporation Announces Closing of Initial Tranche of Over Subscribed Non-Brokered Private PlacementJuly 17, 2020VANCOUVER, BRITISH COLUMBIA, July 17, 2020 — Genix Pharmaceuticals Corporation (TSX-V: GENX)…